Sasolin D400mcg+500mcg

Sasolin D is an FDA-approved fixed-dose combination indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It combines the rapid symptom relief of an alpha-1 adrenergic receptor antagonist (tamsulosin) with the long-term disease-modifying effect of a 5-alpha-reductase inhibitor (dutasteride), which shrinks the prostate over time.

• Established/FDA-approved use: Symptomatic BPH in men with an enlarged prostate, to improve urinary symptoms and reduce the long-term risk of acute urinary retention and the need for BPH-related surgery.
• Not approved for: Prevention of prostate cancer; use in women or children.

Sasolin D is generally reserved for men with moderate-to-severe symptoms and a demonstrably enlarged prostate who are likely to need long-term combination therapy, rather than as first-line therapy for mild symptoms.

Each capsule of Tamsulosin + Dutasteride contains two active ingredients: Tamsulosin Hydrochloride 0.4 mg (as modified-release pellets) and Dutasteride 0.5 mg (in a soft-gelatin matrix), combined within a single hard-gelatin capsule. Inactive ingredients typically include methacrylic acid copolymer, calcium stearate, mono- and di-glycerides, butylated hydroxytoluene, and gelatin capsule shell components, which may vary slightly by manufacturer.

Sasolin D is a fixed-dose oral combination medicine used in adult men for symptomatic benign prostatic hyperplasia (enlargement of the prostate gland). It pairs an alpha-1 blocker that relaxes smooth muscle in the prostate and bladder neck to relieve urinary symptoms quickly, with a 5-alpha-reductase inhibitor that gradually shrinks the enlarged prostate by lowering dihydrotestosterone (DHT) levels, reducing the long-term risk of disease progression.

By combining both mechanisms in a single capsule, Sasolin D offers both immediate symptomatic relief and long-term reduction in prostate volume, decreasing the likelihood of acute urinary retention and the eventual need for BPH-related surgery.

Sasolin D belongs to a combination therapeutic class used for benign prostatic hyperplasia, comprising a selective alpha-1 adrenergic receptor antagonist (tamsulosin) and a 5-alpha-reductase inhibitor (dutasteride). Together these agents are classified under urological agents used for benign prostatic hyperplasia.

Tamsulosin + Dutasteride works through two complementary pharmacological mechanisms.

Tamsulosin (alpha-1 adrenergic antagonist)

Tamsulosin selectively blocks alpha-1A/1D adrenergic receptors in the smooth muscle of the prostate and bladder neck, causing relaxation that improves urine flow and relieves obstructive and irritative BPH symptoms within days to weeks.

Dutasteride (5-alpha-reductase inhibitor)

Dutasteride inhibits both type 1 and type 2 isoenzymes of 5-alpha-reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for prostatic growth. Sustained DHT suppression (greater than 90%) leads to gradual shrinkage of the prostate gland over 3-6 months, reducing the risk of acute urinary retention and the need for surgery.

Together, Tamsulosin + Dutasteride provides both rapid symptomatic improvement and long-term disease modification. Tamsulosin is well absorbed orally with peak plasma levels around 4-8 hours; dutasteride has a very long elimination half-life (approximately 3-5 weeks), reaches steady state by about 6 months of daily dosing, and is metabolized mainly by CYP3A4.

Swallow the capsule of Sasolin D whole with water; do not crush, chew, or open it. Take Sasolin D approximately 30 minutes after the same meal every day to maintain consistent drug absorption. Consistent timing relative to meals helps minimize fluctuations in blood levels.

Sasolin D has the following well-documented, clinically significant interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, itraconazole): increase tamsulosin and dutasteride blood levels; concurrent use with Sasolin D is generally not recommended, or requires caution with close monitoring.
• Other alpha-1 blockers (e.g., doxazosin, terazosin, alfuzosin): additive hypotensive effect; concurrent use with another alpha-blocker is not recommended.
• PDE5 inhibitors (sildenafil, tadalafil): increased risk of symptomatic orthostatic hypotension; use with caution.
• Antihypertensives and diuretics: may increase the risk of orthostatic hypotension, particularly with the first dose or after a dose increase.
• Warfarin: caution advised; monitor coagulation parameters if co-administered, as interaction data are limited.
• CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, cimetidine): may increase tamsulosin exposure.

No dose adjustment is generally required with nifedipine, atenolol, enalapril, theophylline, digoxin, or furosemide. Always inform your physician of all medicines, supplements, and herbal products in use before starting Sasolin D.

The most common side effects of Sasolin D relate to its effects on sexual function and blood pressure regulation:

• Very common/common: Decreased libido, erectile dysfunction/impotence, ejaculation disorders (including retrograde or decreased ejaculation), dizziness, and breast enlargement/tenderness (gynecomastia).
• Less common: Orthostatic hypotension, headache, rhinitis/nasal congestion, asthenia, palpitations.
• Rare but important: Allergic reactions including rash, pruritus, urticaria, and angioedema; priapism; intraoperative floppy iris syndrome during cataract surgery.

Sexual side effects associated with dutasteride (decreased libido, erectile dysfunction, ejaculation disorders) may persist even after stopping Sasolin D in some men. Report any breast lumps, pain, or nipple discharge promptly (see Precautions and Warnings).

Sasolin D is contraindicated for use in women and is not intended for use during pregnancy or lactation under any circumstance. Dutasteride is absorbed through the skin and can cause abnormal development of the external genitalia of a male fetus if a pregnant woman is exposed to it. Women who are pregnant or who may become pregnant should not handle leaking or broken capsules of Sasolin D; if contact occurs, the area should be washed immediately with soap and water. There is no indication for breastfeeding women, as this combination is intended exclusively for adult men with benign prostatic hyperplasia. Any accidental exposure during pregnancy should be reported to a physician immediately.

Orthostatic hypotension: As with other alpha-blockers, Sasolin D can cause a drop in blood pressure on standing, especially with the first dose, after a dose change, or upon resuming therapy after interruption, increasing the risk of dizziness, fainting, and falls. Caution is advised when starting other antihypertensive drugs or PDE5 inhibitors concurrently (see Interactions).

Intraoperative floppy iris syndrome (IFIS): IFIS has been observed during cataract or glaucoma surgery in patients on, or previously treated with, alpha-1 blockers. Inform your ophthalmologist of current or past use of Sasolin D before any eye surgery.

Effect on PSA and prostate cancer detection: Dutasteride lowers serum PSA levels by approximately 50% after 6 months of use, even in the presence of prostate cancer. A new PSA baseline should be established after 3-6 months of treatment, and any confirmed rise from the lowest on-treatment value should be evaluated even if still within the "normal" range. Inform any physician ordering a PSA test that you are taking Sasolin D.

Prostate cancer signal: A slightly higher incidence of high-grade (Gleason 8-10) prostate cancer has been reported with 5-alpha-reductase inhibitors such as dutasteride in clinical trials; the clinical significance is not fully established, but patients should continue routine prostate cancer screening.

Sexual and breast-related effects: Decreased libido, erectile dysfunction, and ejaculation disorders may occur and can persist after stopping treatment in some men. Report any breast lumps, pain, enlargement, or nipple discharge promptly, as rare cases of male breast cancer have been reported with 5-alpha-reductase inhibitors.

Pregnancy exposure precaution: Women who are pregnant or may become pregnant must avoid handling leaking or broken capsules of Sasolin D (see Pregnancy and Lactation).

Blood donation: Men taking Sasolin D should not donate blood until at least 6 months after their last dose, to prevent exposure of a pregnant transfusion recipient to dutasteride.

Hepatic impairment: Use with caution in mild-to-moderate hepatic impairment; not studied in severe hepatic impairment (see Contraindications).

There is no specific antidote for overdose of Sasolin D. Overdose is expected to primarily produce tamsulosin-related effects, such as pronounced hypotension, dizziness, nausea, vomiting, diarrhea, and reflex tachycardia. Doses of dutasteride up to 40 mg/day (80 times the therapeutic dose) for 7 days have not shown significant safety concerns in studies, but data on massive combination overdose are limited.

If overdose of Sasolin D is suspected, seek immediate medical attention or contact a poison control center/emergency services. If hypotension occurs, the patient should be kept lying down (supine position) and given supportive cardiovascular care in a hospital setting; dialysis is unlikely to be beneficial because tamsulosin is highly protein-bound. Do not attempt to manage a suspected overdose of Sasolin D at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Women who are pregnant or may become pregnant should avoid handling this medicine, especially leaking or broken capsules.

Women: Sasolin D is not indicated and is contraindicated for use in women of any age (see Contraindications, Pregnancy and Lactation).

Pediatric patients: Not indicated; safety and efficacy in patients under 18 years have not been established.

Geriatric patients: No overall differences in safety or effectiveness have been observed in patients 65 years and older compared with younger adults; no dose adjustment is required based on age alone.

Renal impairment: No dosage adjustment is necessary in patients with renal impairment; use has not been studied in patients on dialysis or with end-stage renal disease, so caution is advised.

Hepatic impairment: No dosage adjustment is needed for tamsulosin in mild-to-moderate hepatic impairment; dutasteride exposure may be increased in hepatic disease. Sasolin D has not been studied in severe hepatic impairment and is contraindicated in this population (see Contraindications).

Fertility: Dutasteride can reduce sperm count, semen volume, and sperm motility; men planning fertility should discuss this with their physician before starting Sasolin D.

Sasolin D is intended for long-term, continuous use in men with symptomatic BPH, as its disease-modifying benefit (prostate volume reduction and reduced risk of urinary retention or surgery) develops over months and is sustained only with ongoing therapy. Symptom improvement from the tamsulosin component may be noticeable within 2 weeks, while the full benefit of the dutasteride component typically requires 3-6 months or longer of continuous daily use. Treatment duration should be determined by a physician based on symptom response and disease course, and Sasolin D should not be stopped abruptly without medical advice.

Alpha-1 adrenergic receptor antagonist + 5-alpha-reductase inhibitor combination; Urological agent for benign prostatic hyperplasia (BPH)

Tamsulosin + Dutasteride acts via two synergistic mechanisms. Tamsulosin selectively antagonizes alpha-1A and alpha-1D adrenergic receptors concentrated in prostatic and bladder-neck smooth muscle, producing relaxation that reduces bladder outlet obstruction and rapidly improves urinary flow and symptoms. Dutasteride competitively and selectively inhibits both type 1 and type 2 5-alpha-reductase enzymes, which convert testosterone into dihydrotestosterone (DHT), the principal androgen driving prostatic tissue growth; by suppressing DHT by more than 90%, dutasteride causes gradual involution (shrinkage) of the enlarged prostate over several months. This dual mechanism allows Tamsulosin + Dutasteride to relieve symptoms quickly while modifying the underlying disease course over the long term.

X

Sasolin D is not indicated for use in pediatric patients. Safety and effectiveness in individuals under 18 years of age have not been established, and benign prostatic hyperplasia does not occur in children. Sasolin D should never be administered to children or adolescents.